ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: With regard to CML, inhibition of the constitutive tyrosine kinase activity of p210 BCR-ABL [51] with imatinib alleviates the hyperproliferation-induced symptoms [52].